And so having that ability to have the interchangeability designation, I think, will help to guide pharmacists to be able to more actively switch from Humira to the biosimilar specifically. And if they switch, obviously, we have a commanding market share right now in terms of total prescriptions, we’ll be able to get a lot of share of that. So it is a tailwind, I believe, for us for whoever has the interchangeability designation. And I think there’s only about maybe a handful, 3 or 4 actually that will have the interchangeability designation as opposed to others that haven’t initiated the studies. So that’s — I think that’s where it is because it’s in draft form right now, and I think people are going to want to see it, and see that you actually have it, and we’ll have it end of Q2, beginning of Q3 next year.
Operator: Our next question comes from the line of Balaji Prasad with Barclays.
Mikaela Franceschina : This is Mikaela on for Balaji. Just two from us. I guess, can you talk a bit more about the Hadlima ramp into 2024? And I guess, elaborate on just some of the key factors impacting it. And on Women’s Health, will you be able to reverse the weakness seen? And I guess, any further comments on what will be needed here?
Kevin Ali : Yes. For Hadlima, the ramp-up of 2024 will be — I mean, what we see right now is the fact that what AbbVie has been able to do is essentially use their bundling power to essentially exclude — especially in the PBM world. But remember, about 40% of the lives covered right now or what we would call WAC sensitive or what we call low net cost sensitive, it’s just going to be some time until we’re able to get those plants to start opening up. There’s a time lag between kind of the discounts you lose on the AbbVie business as well as kind of compared to the benefit you gain from the discounts that you get going with a biosimilar. We’ll definitely see better business next year, but at the same time — at the same token, we do see that this is another market formation year in 2024.
And then the breakthrough, I believe, will come in 2025, when kind of the floodgates will start to open up slowly and give us an opportunity. That’s why see Hadlima more as kind of a longer-tail business and continued growth, double-digit year-over-year, which will help us in the outer years. There’s no doubt about it. In regards to women — to Women’s Health question, yes, we found some issues this particular quarter, but it doesn’t change the overall trajectory of our Women’s Health business. Let’s remember that in Q3 of 2022, there was 18% growth in the U.S. for Nexplanon. That was because the previous year, there were some COVID issues. So 2023 in this quarter is really a function of a few things. Lapping a very, very strong quarter of last year.
And second, the fact that the go-to-market model has changed in terms of taking price. Right now, people would start to kind of build their inventories in order to take advantage of what the upcoming price change. Now that’s not happening. So that’s what you’re lapping. And then ultimately, you’ll see that kind of come to fruition in the first quarter of next year, where people will start to take inventory at that point of time.
Operator: There are no further questions at this time. I would now like to turn the call over to Kevin Ali for closing remarks.
Kevin Ali : Thank you. It’s been an opportunity for us to kind of show what we’ve been able to accomplish a lot in a very short period of time as a stand-alone company. We’re just a little bit over 2.5 years old. And we’ve got a very talented team dedicated to continuing the growth of Organon’s business. We look forward to the future. There’s been some headwinds in this quarter, but we see them as more transient. China is starting to grow again in Q4, so that overhang is starting to lift, and we see China’s growth opportunities as solid for next year. We’ve taken some changes in regards to our go-to-market model on Nexplanon, and that will continue to show progress for next year as well. And we see opportunities for Hadlima.
And it’s not a question of if, it’s a question of when it starts to open up and ultimately drive more incremental growth for us as a company. So we feel we’re in a good position to continue our work and continue our focus, and we take the opportunity to look forward to speaking to you on the next earnings call. Thank you very much.
Operator: I would like to thank our speakers for today’s presentation, and thank you all for joining us. This now concludes today’s call. You may now disconnect.
